Subscribe
shutterstock_1318400090_the_firstfotolab
16 January 2024AmericasMarisa Woutersen

SCOTUS urged to remedy ‘threat’ to patent law in sleep drug feud

Biotech company submitted a petition challenging an ‘incorrect’ ruling by the Court of Appeals for the Federal Circuit | Earlier decision invalidated several of Vanda’s patents in its sleep drug dispute against a pair of big pharma firms.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Amgen v Sanofi: Scotus grapples with enablement
28 March 2023   As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.
Americas
Gilead avoids $1.2bn patent clash at SCOTUS
10 January 2023   Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.


Editor's picks

BMS blocks biosimilar version of blockbuster cancer drug in India
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025

Editor's picks

Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

More on this story

Americas
Amgen v Sanofi: Scotus grapples with enablement
28 March 2023   As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.
Americas
Gilead avoids $1.2bn patent clash at SCOTUS
10 January 2023   Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.

More on this story

Americas
Amgen v Sanofi: Scotus grapples with enablement
28 March 2023   As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.
Americas
Gilead avoids $1.2bn patent clash at SCOTUS
10 January 2023   Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.

More features

Ninth Circuit revives trade secrets claims in DNA-sequencing spat
Patent pollution: Emissions charter aims to clean up IP
Why Trump’s revenue-raising patent plan is riddled with problems
Harvard’s patent portfolio at risk as Trump turns up the pressure
Weil adds leaders from Latham to head up tech and life sciences
$740M deal ends COVID-19 vaccine feud between CureVac and BioNTech
CyDex trade secrets case tossed by Italian court in rare ruling
Chemical reaction: Why AI drug discovery demands a new IP plan